02 December 2024

SOLASTA Bio completes US$14mn Series A funding round

“SOLASTA Bio has come a long way since we set out on this journey three years ago. Having established operations in the UK and US, we’ve now got an international team with outstanding competencies in technology and agribusiness and, importantly, we have developed our unique technology platform to address grower pain points,” said FRSE, CEO and co-founder of SOLASTA Bio, Shireen Davies PhD. “The results of our field trials have been hugely encouraging, demonstrating high efficacy of biopeptides against target insect pests, as effective or better than standard insecticides. With Series A now secured, it’s time for SOLASTA Bio to kick on to the next level and successfully hit our targets for commercialisation.”